Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMULAB: Pembrolizumab and Local Ablation in Early Stage HCC
NCT03753659Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2019
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Started May 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03753659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753659.